Earnings Ahead

BMRN - BioMarin Pharmaceutical Inc.

76.22 -3.37 -4.23

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

About

Profile

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to


Headquarters

Novato, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BMRN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M
  • BioMarin appoints Alexander Hardy as president and chief executive officer
  • BioMarin Pharmaceutical Q3 2023 Earnings Preview
  • Bernstein upgrades BioMarin to market perform, citing valuation
  • FDA approves use of BioMarin drug Voxzogo in children under 5
  • BioMarin a market perform at Raymond James due to growth concerns
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line
  • BioMarin Pharmaceutical Q2 2023 Earnings Preview
  • BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
  • BioMarin granted FDA nod for hemophilia A gene therapy
  • Eli Lilly, Humana among best health care names in defensive environment - BofA
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M
  • BioMarin Pharmaceutical Q1 2023 Earnings Preview
  • What is behind biotech M&A resurgence?
  • FDA to back accelerated approval pathway for gene therapies
  • BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five
  • BioMarin's Roctavian gets FDA action date extended to end of June
  • BridgeBio soars 55% after Phase 2 data for achondroplasia candidate
  • BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M
  • BioMarin Pharmaceutical Q4 2022 Earnings Preview
Date Price Open High Low Vol Change ER
Oct 9, 2023 87.03 86.85
87.48
86.16
796K -1.23%
Oct 6, 2023 88.11 87.06
89.05
86.97
890K 0.94%
Oct 5, 2023 87.29 85.76
87.55
85.56
958K 1.62%
Oct 4, 2023 85.9 86.33
86.56
85.14
899K -0.34%
Oct 3, 2023 86.19 86.52
87.55
86.15
1.3M -1.02%
 
Oct 2, 2023 87.08 88.35
88.35
85.86
1.7M -1.58%
Sep 29, 2023 88.48 89.57
89.94
88.34
1.6M -0.86%
Sep 28, 2023 89.25 89.54
90.15
88.43
1.6M -1.24%
Sep 27, 2023 90.37 88.74
90.77
88.37
2.3M 2.62%
Sep 26, 2023 88.06 87.17
88.55
86.9
2.2M 1.17%
Sep 25, 2023 87.04 86.28
87.39
85.86
1.3M 0.61%
Sep 22, 2023 86.51 86.28
86.99
85.76
977K 0.28%
Sep 21, 2023 86.27 87.78
88.24
86.19
995K -2.39%
Sep 20, 2023 88.38 88.72
89.66
87.98
919K -0.5%
Sep 19, 2023 88.82 88.84
89.59
88.09
1.2M 0.25%
Sep 18, 2023 88.6 88.07
88.79
87.91
1.0M 0.50%
Sep 15, 2023 88.16 87.38
89.14
87.02
1.5M 0.55%
Sep 14, 2023 87.68 91.99
92.48
87.6
1.4M -4.3%
Sep 13, 2023 91.62 92.3
92.95
90.96
1.1M -0.48%
Sep 12, 2023 92.06 91.2
92.28
90.7
728K 1.32%
Sep 11, 2023 90.86 90.2
90.91
89.61
1.2M 0.74%
Sep 8, 2023 90.19 90.81
91.38
89.85
949K -0.25%
Sep 7, 2023 90.42 90.72
90.99
89.05
1.1M -0.64%
Sep 6, 2023 91 90.35
91.48
90.29
1.2M 0.29%
Sep 5, 2023 90.74 92.48
92.61
90.63
1.1M -2.46%
Sep 1, 2023 93.03 92.21
93.73
91.54
1.0M 1.81%
Aug 31, 2023 91.38 94.42
95.03
91.15
1.4M -2.59%
Aug 30, 2023 93.81 95
95.13
93.52
920K -0.71%
Aug 29, 2023 94.48 93.3
94.64
92.09
1.0M 0.85%
Aug 28, 2023 93.68 94
94.39
92.85
1.3M 0.04%
Aug 25, 2023 93.64 93.54
93.89
91.98
734K 0.54%
Aug 24, 2023 93.14 91.35
93.27
91.04
1.1M 2.27%
Aug 23, 2023 91.07 91.12
91.17
90.04
754K 0.60%
Aug 22, 2023 90.53 89.94
90.86
89.79
485K 0.73%
Aug 21, 2023 89.87 88.89
90.38
88.74
935K 0.92%
Aug 18, 2023 89.05 89.27
90.16
88.46
1.2M -0.39%
Aug 17, 2023 89.4 90
90.78
89.32
704K -0.67%
Aug 16, 2023 90 90
90.73
89.45
660K -0.74%
Aug 15, 2023 90.67 90.2
91.18
89.72
610K 0.42%
Aug 14, 2023 90.29 89.29
90.77
89.01
776K 0.98%
Aug 11, 2023 89.41 90.57
90.78
88.93
1.0M -1.65%
Aug 10, 2023 90.91 93.21
93.4
89.78
1.3M -2.49%
Aug 9, 2023 93.23 91.29
94.07
91.24
1.7M 2.89%
Aug 8, 2023 90.61 88.29
90.88
87.93
1.4M 3.17%
Aug 7, 2023 87.83 88.1
88.17
87.25
828K -0.8%
Aug 4, 2023 88.54 87.88
89.43
87.88
1.1M 0.91%
Aug 3, 2023 87.74 88.37
88.54
87.69
1.1M -0.74%
Aug 2, 2023 88.39 88.85
89.62
87.13
1.1M -0.69%
Aug 1, 2023 89 87
89.08
84.65
3.2M 1.22%
Jul 31, 2023 87.93 87.94
88.05
87.07
1.5M 0.37%
Jul 28, 2023 87.61 87.31
87.72
86.25
1.2M 1.21%
Jul 27, 2023 86.56 87.77
87.78
86.06
1.2M -0.81%
Jul 26, 2023 87.27 87.65
88.05
86.91
951K -0.64%
Jul 25, 2023 87.83 87.54
88.17
87.46
876K 0.48%
Jul 24, 2023 87.41 87.58
88.58
87.34
854K -0.35%
Jul 21, 2023 87.72 87.91
88.3
87.38
1.2M 0.21%
Jul 20, 2023 87.54 86.91
87.89
86.63
845K 0.53%
Jul 19, 2023 87.08 86.93
87.6
86.33
960K 0.93%
Jul 18, 2023 86.28 86.66
87.08
85.66
1.2M -0.45%
Jul 17, 2023 86.67 85.87
87.36
85.5
960K 0%